Brokerages Set AstraZeneca PLC (LON:AZN) PT at GBX 7,542.80

Shares of AstraZeneca PLC (LON:AZN) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is GBX 7,542.80 ($97.65).

AZN has been the subject of several research reports. Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.81) price target on shares of AstraZeneca in a research note on Wednesday. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th.

AstraZeneca Price Performance

Shares of AZN opened at £113.62 ($147.10) on Friday. The company has a market cap of £218.61 billion, a P/E ratio of 31.14, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a fifty-two week low of GBX 9,670 ($125.19) and a fifty-two week high of £133.88 ($173.33). The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. The firm’s 50 day moving average price is £115.78 and its 200 day moving average price is £112.80.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.